|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Unbilled receivable from government contracts | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Prepaid clinical services, long-term | ||||||||||||||||||||
| Right-of-use assets, net | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other long-term assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Government Contract | ||||||||||||||||||||
| Collaboration Revenue | ||||||||||||||||||||
| Total deferred revenue | ||||||||||||||||||||
| Other accrued current liabilities | ||||||||||||||||||||
| Current portion of operating lease liability | ||||||||||||||||||||
| Current portion of liability related to sale of future royalties | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Operating lease liability, net of current portion | ||||||||||||||||||||
| Deferred collaboration revenue, net of current portion | ||||||||||||||||||||
| Collaboration Revenue | ||||||||||||||||||||
| Total deferred collaboration revenue, net of current portion | ||||||||||||||||||||
| Liability related to sale of future royalties, net of current portion | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock: $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Common stock: $0.0001 par value; 350,000,000 shares authorized as of June 30, 2026 and December 31, 2025; 242,973,040 shares issued and 242,835,358 shares outstanding as of June 30, 2026 and 240,742,681 shares issued and 240,494,594 shares outstanding as of December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Treasury stock at cost, 137,682 shares as of June 30, 2026 and 248,087 shares as of December 31, 2025 | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
